The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients
Background The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing s...
Gespeichert in:
| Veröffentlicht in: | The International journal of biological markers 2021-11, Vol.36 (4), p.27-35 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 4 |
| container_start_page | 27 |
| container_title | The International journal of biological markers |
| container_volume | 36 |
| creator | Zhang, Xintong Ma, Shang Chen, Yan Yin, Yanjun Bai, Wanqiu Tan, Jinjing Shi, Guangli |
| description | Background
The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing surgery or medical treatment, to evaluate its potential prognostic value.
Methods
The study cohort included 83 NSCLC patients who underwent surgery, 37 NSCLC patients who underwent medical treatment, 50 healthy controls, and 52 disease controls. Serum levels of IDH1 were assayed by enzyme-linked immunoassay. Tumor biomarkers including carcinoembryonic antigen, squamous cell carcinoma, neuron-specific enolase, CYFRA21-1, and pro-gastrin-releasing peptide—which are currently used in clinical practice—were measured by automatic immunoanalyzers.
Results
Serum IDH1 was significantly higher in patients with NSCLC compared with healthy people or patients with benign lung diseases (p < 0.001). The area under the receiver operating characteristic curve for diagnosis and differential diagnosis were 0.897 and 0.879, respectively, which were superior to the five tumor markers. Serum IDH1 levels decreased in most patients after surgery, with the most dramatic changes in patients with stage I tumors compared with stage II and III. Analyses of changes in the serum IDH1 level of patients after receiving chemotherapy or targeted therapy revealed that for patients with progressive disease, serum IDH1 increased significantly after treatment; for patients with partial response or stable disease, it decreased steadily.
Conclusion
IDH1 has potential prognostic value and may be used as a marker for the monitoring of treatment efficacy. |
| doi_str_mv | 10.1177/17246008211052571 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2596455223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_17246008211052571</sage_id><sourcerecordid>2596455223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-6f4d142137667105875f440fba1eacca1799c1b50d2af954653ca5c4ae82f2fd3</originalsourceid><addsrcrecordid>eNp1kU1vGyEQhlHUqHY-fkAvFVIvvWzCsHx4j5WVJpEi5ZKcV2MWHKw1uMAe_O-L5TSNWuUAjGaed3hhCPkC7ApA62vQXCjGFhyASS41nJD5Idcckp_exTNylvOGMQ5Mq89k1gqtQMNiTjZPL5b6HI0vCYulg33ZDymubcBsKdQSRbqLxYbicaS7WgoxF2-oD4M3WGKirq4QQ5O3OI7U2LqNU1hTg8HYRHdYfJXnC3LqcMz28vU8J88_b56Wd83D4-398sdDYwRAaZQTAwgOrVZK13cttHRCMLdCsGgMgu46AyvJBo6uk0LJ1qA0Au2CO-6G9px8P_atZn9NNpd-6_PBFQYbp9xz2SkhJedtRb_9g27ilEJ113NVHXDO2q5ScKRMijkn6_pd8ltM-x5YfxhE_98gqubra-dptbXDm-LPz1fg6ghkXNu_137c8TfKrI_h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2613722039</pqid></control><display><type>article</type><title>The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zhang, Xintong ; Ma, Shang ; Chen, Yan ; Yin, Yanjun ; Bai, Wanqiu ; Tan, Jinjing ; Shi, Guangli</creator><creatorcontrib>Zhang, Xintong ; Ma, Shang ; Chen, Yan ; Yin, Yanjun ; Bai, Wanqiu ; Tan, Jinjing ; Shi, Guangli</creatorcontrib><description>Background
The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing surgery or medical treatment, to evaluate its potential prognostic value.
Methods
The study cohort included 83 NSCLC patients who underwent surgery, 37 NSCLC patients who underwent medical treatment, 50 healthy controls, and 52 disease controls. Serum levels of IDH1 were assayed by enzyme-linked immunoassay. Tumor biomarkers including carcinoembryonic antigen, squamous cell carcinoma, neuron-specific enolase, CYFRA21-1, and pro-gastrin-releasing peptide—which are currently used in clinical practice—were measured by automatic immunoanalyzers.
Results
Serum IDH1 was significantly higher in patients with NSCLC compared with healthy people or patients with benign lung diseases (p < 0.001). The area under the receiver operating characteristic curve for diagnosis and differential diagnosis were 0.897 and 0.879, respectively, which were superior to the five tumor markers. Serum IDH1 levels decreased in most patients after surgery, with the most dramatic changes in patients with stage I tumors compared with stage II and III. Analyses of changes in the serum IDH1 level of patients after receiving chemotherapy or targeted therapy revealed that for patients with progressive disease, serum IDH1 increased significantly after treatment; for patients with partial response or stable disease, it decreased steadily.
Conclusion
IDH1 has potential prognostic value and may be used as a marker for the monitoring of treatment efficacy.</description><identifier>ISSN: 1724-6008</identifier><identifier>ISSN: 0393-6155</identifier><identifier>EISSN: 1724-6008</identifier><identifier>DOI: 10.1177/17246008211052571</identifier><identifier>PMID: 34761718</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antigens, Neoplasm ; Biomarkers, Tumor ; Carcinoembryonic Antigen ; Carcinoma, Non-Small-Cell Lung - genetics ; Chemotherapy ; Dehydrogenases ; Differential diagnosis ; Disease ; Gastrin ; Gastrin-releasing peptide ; Humans ; Isocitrate dehydrogenase ; Isocitrate Dehydrogenase - genetics ; Keratin-19 - genetics ; Lung cancer ; Lung diseases ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Medical prognosis ; Medical treatment ; Non-small cell lung carcinoma ; Patients ; Phosphopyruvate hydratase ; Prognosis ; Serum levels ; Small cell lung carcinoma ; Squamous cell carcinoma ; Surgery ; Tumor markers ; Tumors</subject><ispartof>The International journal of biological markers, 2021-11, Vol.36 (4), p.27-35</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-6f4d142137667105875f440fba1eacca1799c1b50d2af954653ca5c4ae82f2fd3</citedby><cites>FETCH-LOGICAL-c411t-6f4d142137667105875f440fba1eacca1799c1b50d2af954653ca5c4ae82f2fd3</cites><orcidid>0000-0003-3534-8376</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/17246008211052571$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/17246008211052571$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,864,21966,27853,27924,27925,44945,45333</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34761718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xintong</creatorcontrib><creatorcontrib>Ma, Shang</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Yin, Yanjun</creatorcontrib><creatorcontrib>Bai, Wanqiu</creatorcontrib><creatorcontrib>Tan, Jinjing</creatorcontrib><creatorcontrib>Shi, Guangli</creatorcontrib><title>The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients</title><title>The International journal of biological markers</title><addtitle>Int J Biol Markers</addtitle><description>Background
The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing surgery or medical treatment, to evaluate its potential prognostic value.
Methods
The study cohort included 83 NSCLC patients who underwent surgery, 37 NSCLC patients who underwent medical treatment, 50 healthy controls, and 52 disease controls. Serum levels of IDH1 were assayed by enzyme-linked immunoassay. Tumor biomarkers including carcinoembryonic antigen, squamous cell carcinoma, neuron-specific enolase, CYFRA21-1, and pro-gastrin-releasing peptide—which are currently used in clinical practice—were measured by automatic immunoanalyzers.
Results
Serum IDH1 was significantly higher in patients with NSCLC compared with healthy people or patients with benign lung diseases (p < 0.001). The area under the receiver operating characteristic curve for diagnosis and differential diagnosis were 0.897 and 0.879, respectively, which were superior to the five tumor markers. Serum IDH1 levels decreased in most patients after surgery, with the most dramatic changes in patients with stage I tumors compared with stage II and III. Analyses of changes in the serum IDH1 level of patients after receiving chemotherapy or targeted therapy revealed that for patients with progressive disease, serum IDH1 increased significantly after treatment; for patients with partial response or stable disease, it decreased steadily.
Conclusion
IDH1 has potential prognostic value and may be used as a marker for the monitoring of treatment efficacy.</description><subject>Antigens, Neoplasm</subject><subject>Biomarkers, Tumor</subject><subject>Carcinoembryonic Antigen</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Chemotherapy</subject><subject>Dehydrogenases</subject><subject>Differential diagnosis</subject><subject>Disease</subject><subject>Gastrin</subject><subject>Gastrin-releasing peptide</subject><subject>Humans</subject><subject>Isocitrate dehydrogenase</subject><subject>Isocitrate Dehydrogenase - genetics</subject><subject>Keratin-19 - genetics</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Phosphopyruvate hydratase</subject><subject>Prognosis</subject><subject>Serum levels</subject><subject>Small cell lung carcinoma</subject><subject>Squamous cell carcinoma</subject><subject>Surgery</subject><subject>Tumor markers</subject><subject>Tumors</subject><issn>1724-6008</issn><issn>0393-6155</issn><issn>1724-6008</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU1vGyEQhlHUqHY-fkAvFVIvvWzCsHx4j5WVJpEi5ZKcV2MWHKw1uMAe_O-L5TSNWuUAjGaed3hhCPkC7ApA62vQXCjGFhyASS41nJD5Idcckp_exTNylvOGMQ5Mq89k1gqtQMNiTjZPL5b6HI0vCYulg33ZDymubcBsKdQSRbqLxYbicaS7WgoxF2-oD4M3WGKirq4QQ5O3OI7U2LqNU1hTg8HYRHdYfJXnC3LqcMz28vU8J88_b56Wd83D4-398sdDYwRAaZQTAwgOrVZK13cttHRCMLdCsGgMgu46AyvJBo6uk0LJ1qA0Au2CO-6G9px8P_atZn9NNpd-6_PBFQYbp9xz2SkhJedtRb_9g27ilEJ113NVHXDO2q5ScKRMijkn6_pd8ltM-x5YfxhE_98gqubra-dptbXDm-LPz1fg6ghkXNu_137c8TfKrI_h</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Zhang, Xintong</creator><creator>Ma, Shang</creator><creator>Chen, Yan</creator><creator>Yin, Yanjun</creator><creator>Bai, Wanqiu</creator><creator>Tan, Jinjing</creator><creator>Shi, Guangli</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3534-8376</orcidid></search><sort><creationdate>20211101</creationdate><title>The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients</title><author>Zhang, Xintong ; Ma, Shang ; Chen, Yan ; Yin, Yanjun ; Bai, Wanqiu ; Tan, Jinjing ; Shi, Guangli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-6f4d142137667105875f440fba1eacca1799c1b50d2af954653ca5c4ae82f2fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens, Neoplasm</topic><topic>Biomarkers, Tumor</topic><topic>Carcinoembryonic Antigen</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Chemotherapy</topic><topic>Dehydrogenases</topic><topic>Differential diagnosis</topic><topic>Disease</topic><topic>Gastrin</topic><topic>Gastrin-releasing peptide</topic><topic>Humans</topic><topic>Isocitrate dehydrogenase</topic><topic>Isocitrate Dehydrogenase - genetics</topic><topic>Keratin-19 - genetics</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Phosphopyruvate hydratase</topic><topic>Prognosis</topic><topic>Serum levels</topic><topic>Small cell lung carcinoma</topic><topic>Squamous cell carcinoma</topic><topic>Surgery</topic><topic>Tumor markers</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xintong</creatorcontrib><creatorcontrib>Ma, Shang</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Yin, Yanjun</creatorcontrib><creatorcontrib>Bai, Wanqiu</creatorcontrib><creatorcontrib>Tan, Jinjing</creatorcontrib><creatorcontrib>Shi, Guangli</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of biological markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xintong</au><au>Ma, Shang</au><au>Chen, Yan</au><au>Yin, Yanjun</au><au>Bai, Wanqiu</au><au>Tan, Jinjing</au><au>Shi, Guangli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients</atitle><jtitle>The International journal of biological markers</jtitle><addtitle>Int J Biol Markers</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>36</volume><issue>4</issue><spage>27</spage><epage>35</epage><pages>27-35</pages><issn>1724-6008</issn><issn>0393-6155</issn><eissn>1724-6008</eissn><abstract>Background
The serum isocitrate dehydrogenase 1(IDH1) level is significantly elevated in patients with non-small cell lung cancer (NSCLC) and has important clinical value as a marker for early diagnosis. This study examined the dynamic changes of serum IDH1 levels of patients with NSCLC undergoing surgery or medical treatment, to evaluate its potential prognostic value.
Methods
The study cohort included 83 NSCLC patients who underwent surgery, 37 NSCLC patients who underwent medical treatment, 50 healthy controls, and 52 disease controls. Serum levels of IDH1 were assayed by enzyme-linked immunoassay. Tumor biomarkers including carcinoembryonic antigen, squamous cell carcinoma, neuron-specific enolase, CYFRA21-1, and pro-gastrin-releasing peptide—which are currently used in clinical practice—were measured by automatic immunoanalyzers.
Results
Serum IDH1 was significantly higher in patients with NSCLC compared with healthy people or patients with benign lung diseases (p < 0.001). The area under the receiver operating characteristic curve for diagnosis and differential diagnosis were 0.897 and 0.879, respectively, which were superior to the five tumor markers. Serum IDH1 levels decreased in most patients after surgery, with the most dramatic changes in patients with stage I tumors compared with stage II and III. Analyses of changes in the serum IDH1 level of patients after receiving chemotherapy or targeted therapy revealed that for patients with progressive disease, serum IDH1 increased significantly after treatment; for patients with partial response or stable disease, it decreased steadily.
Conclusion
IDH1 has potential prognostic value and may be used as a marker for the monitoring of treatment efficacy.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34761718</pmid><doi>10.1177/17246008211052571</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3534-8376</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1724-6008 |
| ispartof | The International journal of biological markers, 2021-11, Vol.36 (4), p.27-35 |
| issn | 1724-6008 0393-6155 1724-6008 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2596455223 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Antigens, Neoplasm Biomarkers, Tumor Carcinoembryonic Antigen Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Dehydrogenases Differential diagnosis Disease Gastrin Gastrin-releasing peptide Humans Isocitrate dehydrogenase Isocitrate Dehydrogenase - genetics Keratin-19 - genetics Lung cancer Lung diseases Lung Neoplasms - diagnosis Lung Neoplasms - genetics Medical prognosis Medical treatment Non-small cell lung carcinoma Patients Phosphopyruvate hydratase Prognosis Serum levels Small cell lung carcinoma Squamous cell carcinoma Surgery Tumor markers Tumors |
| title | The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A39%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20isocitrate%20dehydrogenase%201%20is%20a%20potential%20prognostic%20indicator%20for%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=The%20International%20journal%20of%20biological%20markers&rft.au=Zhang,%20Xintong&rft.date=2021-11-01&rft.volume=36&rft.issue=4&rft.spage=27&rft.epage=35&rft.pages=27-35&rft.issn=1724-6008&rft.eissn=1724-6008&rft_id=info:doi/10.1177/17246008211052571&rft_dat=%3Cproquest_cross%3E2596455223%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2613722039&rft_id=info:pmid/34761718&rft_sage_id=10.1177_17246008211052571&rfr_iscdi=true |